Neurosurg Focus 44 (4): E4, 2018 M eningioMas are the most common primary intracranial neoplasm. They are more common in women and their incidence rises with increasing age. 3, 5, 10 Meningiomas are categorized into 3 histopathological grades by the WHO, with 70%-95% of meningiomas being classified as WHO grade I. 15, 17, 18, 20 Symptomatic tumors are treated primarily with surgery or radiotherapy. The WHO grade II and III meningiomas are more aggressive, with higher rates of mitosis, and are more likely to recur after surgery and require adjuvant treatment with radiotherapy. 23 Therefore, determining preoperative risk factors for higher tumor grade can provide useful information for both neurosurgeons and patients.
experience we anecdotally observed that larger tumors tended to be higher grade. Thus, we performed a retrospective study to evaluate whether tumor size was associated with tumor grade.
Methods Study Design, Setting, Size, and Participants
We performed a retrospective chart review of patients who underwent resection of meningioma at the University of California, San Francisco, between 1985 and 2016. Variables were collected from provider notes, pathology records, operative notes, and radiological reports. Patients were excluded if no size information was available, the tumor was located in the spine, or the tumor was WHO grade III. Grade III tumors were removed due to their rarity in our data set. The manuscript was drafted consistent with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement. 28 The institutional review board at our institution approved this study.
Demographic and Tumor Variables
Demographic variables included age, sex, and followup duration. Tumor grade was obtained from the pathology report at the time of resection, and thus tumors resected prior to 2007 will be biased toward WHO grade I due to the 2007 WHO grading changes. Tumor size was determined from the preoperative MRI scan and radiologist report. The largest diameter in either the anterior-posterior, transverse, or craniocaudal dimension was used as an overall surrogate for tumor size. Tumor locations were obtained from operative and radiology reports, which included convexity, falx, parasagittal, tentorium, cavernous sinus, clinoid, parasellar, tuberculum sellae, planum sphenoidale, olfactory groove, orbital, middle fossa, sphenoid wing, clivus, cerebellopontine angle, posterior fossa, petroclival, petrous, foramen magnum, jugular foramen, skull base, intraventricular, and multifocal. The locations were further categorized into 3 groups: convexity/falx/ parasagittal, skull base tumors, and other. Skull base location was defined as cavernous sinus, cerebellopontine angle, clinoid, clivus, foramen magnum, jugular foramen, middle fossa, olfactory groove, orbital, parasellar, petroclival, petrous, planum sphenoidale, posterior fossa, skull base, sphenoid wing, and tuberculum sellae. Other locations included intraventricular and multifocal tumors that could not be easily classified into skull base, convexity, or falx locations.
Study Bias
This is a retrospective study, and thus is limited by selection bias. No patients were excluded if they had information regarding the variables of interest in the chart, thus limiting selection bias.
Statistical Analysis
All statistical analyses were performed using JMP Pro (version 13.0; SAS Institute, Inc.). Demographic data were assembled and analyzed in the standard fashion. For categorical data, Pearson's chi-square (multiple categories) or Fisher exact (2 categories) tests were reported. Univariate and multivariate logistic regression was performed and used to calculate odds ratios. A recursive partitioning analysis (RPA) was performed to split the continuous size data into clinically relevant groups. The RPA was also used with multiple variables to determine groups at risk for having a WHO grade II tumor. The number of partitions performed was based on maximal R 2 as calculated by k-fold cross-validation (k = 5).
Results

Demographics and Tumor Characteristics
A final sample size of 1113 patients (mean age 55.7 years, range 8-90 years, 73.9% female) was obtained from the electronic medical record ( Table 1 ). The majority of patients presented with either a headache or cranial nerve deficit. The WHO grade at the time of resection was used to assign the WHO grade. The majority (81%) of patients had a WHO grade I tumor and 19% were WHO grade II. The mean tumor size was 3.8 cm (SD 1.8 cm), and the median size was 3.6 cm (range 0.2-13 cm). Roughly half of the patients in our study had meningiomas located in the skull base, 40% of tumors were located in the falx/ parasagittal or convexity area, and the remaining 10% of tumors were found in other locations (Table 2) .
Risk Factors for WHO Grade II
We performed univariate logistic regression to determine if age, sex, tumor location, and tumor size were significantly associated with WHO grade (Table 3) . Age was not a significant predictor of grade (p = 0.61). Tumor size was significantly associated with a meningioma being WHO grade II ( Fig. 1 ; p < 0.001). Tumor convexity/ falx/parasagittal location (OR 1.90, 95% CI 1.38-2.63, p < 0.001) and other location (OR 1.71, 95% CI 1.02-2.86, To identify meaningful size cutoff points for risk of higher-grade tumors, we performed RPA. We identified 3.2 cm as the optimal split, and divided the tumors into groups of < 3 cm, 3-6 cm, and > 6 cm. We then performed multivariate logistic regression and calculated odds ratios for the groups (Table 4) . Last, we used a multivariate RPA to identify subgroups at highest risk for having a WHO grade II tumor. The k-fold cross-validation was used to determine that 3 splits was the optimal number of splits.
The first split was tumor size at 3.2 cm, which increased the likelihood of a WHO grade II tumor (23.9% vs 11.3%). The second split was on sex, with male patients having an increased likelihood of a WHO grade II tumor compared to female patients (32.5% vs 20.0%). Finally, the third split was made for tumors < 3.2 cm based on location, with non-skull base tumors having an increased likelihood of a WHO grade II tumor (16.6% vs 8.8%) (Fig. 2) .
Discussion
Key Results
Our results show that larger tumor size is associated with an increased likelihood of a meningioma being WHO grade II, even after controlling for interactions with the known risk factors of sex and meningioma location. 
Interpretation of Results
Here, we show that larger meningiomas are more likely to be WHO grade II tumors. Importantly, this relationship was maintained as an independent risk factor even after crossing with tumor location and male sex in a multivariate analysis. Consistent with prior studies, skull base tumors were less likely to be higher grade than convexity and falx/parasagittal meningiomas. 8, 19 Male sex, another known risk factor for atypical meningioma, was also found to be significant in our study. 6, 16, 19, 24 As with prior studies, age was not related to WHO grade. Interestingly, the RPA found that among size, sex, and location, tumor size was the most important dividing factor between the likelihood of WHO grade I and II tumors. It also identified a subset of male patients with large tumors who are at particularly high risk. Figure 1 shows how this risk continues to increase with increasing tumor size. These findings are useful when discussing management plans with patients and when preparing expectations for care that may be more likely to include adjuvant radiotherapy. 7 A recent report found that 20% of giant meningiomas (i.e., > 5 cm) were WHO grade II or III. 21 Furthermore, in that study, tumor location also influenced recurrence-free survival. Another retrospective analysis reported that tumor size was related to disease-free survival for patients with atypical meningiomas who received radiotherapy.
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Our findings add to these prior reports by being the first study to demonstrate that tumor size is directly related to tumor grade.
The findings in this study raise the question of what mechanisms drive the relationship between tumor size and grade. Simplistically thinking, one possibility is that grade II tumors grow more quickly than grade I tumors and are more likely to reach a larger size. However, if that were the case, one might imagine that a faster-growing tumor would present earlier, because rapidly growing tumors often become symptomatic at a smaller size. Alternatively, it is possible that once a slow-growing tumor reaches a large size, a microenvironment develops (perhaps caused by hypoxia) that facilitates the transformation of the tumor to a more aggressive phenotype. Moving forward, we will need to turn to the laboratory to identify what mechanisms drive meningioma growth and cause them to become higher grade.
Significant progress has been made in the last several years to identify what genes are mutated in meningioma. In addition to NF2, mutations have been found in TRAF7, SMO, KLF4, PI3K, and AKT1. 1, 8 Mutations in POLR2A were identified in recurrent meningiomas.
9 Multiple independent groups have shown that TERT promoter mutations are associated with shorter time to recurrence, survival, and overall poor prognosis. 2, 12, 13, 25 In addition to somatic mutations, specific DNA methylation patterns have recently been discovered that complement known chromosomal rearrangements that are associated with tumor grade and survival. 4, 26 In contrast to mechanisms occurring within the meningioma, another possibility is that the immune environment and tumor-immune system interaction may alter tumor growth and drive the development of large size. Interestingly, we recently found that increased PD-L1 expression in meningioma was associated with shorter survival. 14 We hypothesize that the relationship between meningioma size and grade reflects changes in the molecular landscape of each individual tumor and the way in which individual meningioma interacts with the surrounding microenvironment and immune system. Contin- ued basic and translational research efforts are needed to further characterize these drivers of meningioma growth and, we hope, to identify additional molecular targets for treatment.
Limitations of the Study
This study is limited by its retrospective design. In addition, the criteria for WHO classification changed during the years of this study, and regrading all the samples in this series is not practical. With the 2007 WHO classification, there are more meningiomas classified as grade II, which means that our study probably underestimates the incidence of grade II tumors. 27 However, the rate of atypical meningiomas in our cohort is similar to that in previously published series. 22 Another limitation is the use of tumor diameter as a proxy for overall tumor size because meningiomas can take many shapes. Retrospectively performing volumetric analysis was beyond the scope of the current study. Future prospective studies with volumetric analysis and contemporary grading criteria would be an excellent addition to strengthen these results.
Generalizability of the Findings
One of the most significant strengths of this study is its very large sample size, which makes these results widely generalizable and applicable to all providers treating this disease and to patients who are diagnosed with meningioma.
Conclusions
In this study, we identified tumor size as an independent risk factor for a meningioma to be WHO grade II. In addition, we recapitulate other studies showing that male sex and tumor location are also risk factors for a meningioma to be WHO grade II. Predicting tumor grade from radiological factors such as preoperative tumor size and location can impact surgical decision making, operative planning, and treatment strategies.
